Press Releases
  Date Title View
Rockville, MD., January 30, 2009 — Supernus Pharmaceuticals Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN810 in the treatment of serious conduct problems in the setting of ADHD. The trial is a proof-of-concept, open-label study with pediatric subjects randomiz...
Posted: Jan 30, 2009
Rockville, MD., December 17, 2008 — Supernus Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase III clinical trial for its lead product SPN-804. The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of SPN-804 for the adjunctive treatment o...
Posted: Dec 17, 2008
Rockville, MD, April 23, 2008 — Supernus Pharmaceuticals, Inc. today announced that it closed a private placement to institutional investors of $75 million in aggregate principal amount of non-convertible, non-recourse promissory notes. The notes are secured by royalties generated from sales of Oracea®...
Posted: Apr 23, 2008
September 19, 2007 - Indevus Pharmaceuticals, Inc (Nasdaq: IDEV), a Supernus Pharmaceuticals Partner, today announced that Allergan, Inc. (NYSE: AGN), through its acquisition of Esprit Pharma, has obtained the United States rights to Sanctura® and Sanctura® XR. CONTACT: Russell "Rip" Wilson Chief Financial Officer Supe...
Posted: Sep 19, 2007
August 6, 2007 - Indevus Pharmaceuticals, Inc (Nasdaq: IDEV), a Supernus Pharmaceuticals Partner, today announced that Sanctura® XR (trospium chloride extended release capsules) has been approved by the U.S. Food and Drug Administration (FDA). CONTACT: Russell "Rip" Wilson Chief Financial Officer Supernus Pharmaceu...
Posted: Aug 6, 2007
Posted: Jun 26, 2006
Posted: Jun 13, 2006
Rockville, MD, February 21, 2006 - Supernus Pharmaceuticals, Inc., announces the closing of a second round of financing raising an additional $17.5 million. This completes the Series A funding for a total of $45 million. The company announced last month the closing of the first round of financing and the acquisition of substantially all the as...
Posted: Feb 21, 2006
Posted: Jan 12, 2006
FirstPrevious
...
15
= add release to Briefcase